The estimated Net Worth of Dov Elefant is at least $337 mil dollars as of 28 December 2020. Mr. Elefant owns over 7,407 units of Cellectar Biosciences Inc stock worth over $24,568 and over the last 9 years he sold CLRB stock worth over $0. In addition, he makes $312,437 as Chief Financial Officer y Vice President at Cellectar Biosciences Inc.
Sign up
Mr. Elefant CLRB stock SEC Form 4 insiders trading
Dov has made over 2 trades of the Cellectar Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 7,407 units of CLRB stock worth $9,999 on 28 December 2020.
The largest trade he's ever made was buying 7,407 units of Cellectar Biosciences Inc stock on 28 December 2020 worth over $9,999. On average, Dov trades about 1,679 units every 29 days since 2015. As of 28 December 2020 he still owns at least 11,755 units of Cellectar Biosciences Inc stock.
You can see the complete history of Mr. Elefant stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dov Elefant biography
Dov Elefant serves as Chief Financial Officer, Vice President of the Company. Mr. Elefant was appointed our Vice President and Chief Financial Officer in September 2019. Mr. Elefant has more than 20 years of industry experience at both public and private biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Akari Therapeutics PLC, a publicly-traded biopharmaceutical company specializing in treatments for autoimmune and inflammatory diseases, from September 2015 to August 2019. Prior to his service at Akari Therapeutics, PLC, Mr. Elefant served as Chief Financial Officer of Celsus Therapeutics, Inc., a publicly-traded biopharmaceutical company, from January 2012 to September 2015. Mr. Elefant holds a B.S. in accounting from Yeshiva University.
What is the salary of Dov Elefant?
As the Chief Financial Officer y Vice President of Cellectar Biosciences Inc, the total compensation of Dov Elefant at Cellectar Biosciences Inc is $312,437. There are 5 executives at Cellectar Biosciences Inc getting paid more, with James Caruso having the highest compensation of $934,460.
How old is Dov Elefant?
Dov Elefant is 52, he's been the Chief Financial Officer y Vice President of Cellectar Biosciences Inc since 2019. There are 7 older and 4 younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
What's Dov Elefant's mailing address?
Dov's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC.,, 100 CAMPUS DRIVE, FLORHAM, NJ, 07932.
Insiders trading at Cellectar Biosciences Inc
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm y John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
What does Cellectar Biosciences Inc do?
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
What does Cellectar Biosciences Inc's logo look like?
Complete history of Mr. Elefant stock trades at Akari Therapeutics Plc y Cellectar Biosciences Inc
Cellectar Biosciences Inc executives and stock owners
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include:
-
James Caruso,
President, Chief Executive Officer, Director -
James V. Caruso,
Pres, CEO & Director -
Jarrod Longcor,
Chief Business Officer -
Jarrod Longcor,
Chief Operating Officer -
John Friend,
Vice President, Chief Medical Officer -
Dov Elefant,
Chief Financial Officer, Vice President -
Douglas Swirsky,
Independent Chairman of the Board -
John Neis,
Independent Director -
Stefan Loren,
Independent Director -
Stephen Hill,
Independent Director -
Frederick Driscoll,
Independent Director -
Gregory J. Lynch Esq.,
Sec. -
Dr. Laurence Reilly L.L.M., LL.M, M.D., MBChB,
Interim Chief Medical Officer -
Chad J. Kolean CPA, CPA,
Chief Financial Officer -
Richard Hertzberg,
-
Brian M Posner,
Chief Financial Officer -
Igor D Grachev,
Chief Medical Officer -
Jamey P Weichert,
Chief Scientific Officer -
Paul L Berns,
Director -
Investment Company, Inc. Awm,
10% owner -
John Patrick Genn,
VP of Business Development -
Cameron Szakacs,
VP of Clinical Development -
Simon Pedder,
President and CEO -
Austin W & Greenhouse David...,
10% owner -
Asher Chanan Khan,
Director -
Chad J Kolean,
Chief Financial Officer -
Darrell Shane Lea,
Chief Commercial Officer -
Andrei Shustov,
Senior Vice President, Medical